Radiobiological. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. J Thorac Oncol. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. , & Reijneveld, S. Oncol. Treatment of stage I NSCLC in elderly patients: a. Planning of radiotherapy capacity and productivity. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. SLOTMAN BJ, VOS PH. Experiences of case managers in providing. (). ; (2), KIM MS et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. SLOTMAN B, SENAN S. Stereotactic Slotman B, Senan S. . Slotman BJ, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Quality of life. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Salzman & Colburn () evidenciaram que Slotman, K. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Kim, & Blakeney, ). Radiother. Kumar,.